Naoko Takebe to DNA, Neoplasm
This is a "connection" page, showing publications Naoko Takebe has written about DNA, Neoplasm.
Connection Strength
0.153
-
Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development. Jpn J Clin Oncol. 2015 Nov; 45(11):1001-6.
Score: 0.125
-
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs. 2014 Oct; 32(5):1005-16.
Score: 0.028